PCPiergiorgio Cao

Piergiorgio Cao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Piergiorgio Cao has a total of 95 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Endovaskuläre und offene Versorgung thorakoabdomineller Aortenaneurysmen

    by C Ferrer, P Cao, P De Rango

    Insgesamt war die Sterblichkeit nach endovaskulärer und offener Versorgung thorakoabdomineller Aortenaneurysmen kurz- und mittelfristig vergleichbar. Allerdings war die EVAR beim Auftreten respiratorischer Komplikationen – prolongierte Intubation > 72 oder Notwendigkeit einer Reintubation – deutlich überlegen. Patienten mit entsprechendem Risiko könnten also von dem endovaskulären Verfahren profitieren. Auch wenn echte Langzeitdaten noch fehlen, könnte ihre Auswertung doch helfen, meinen die Mediziner abschließend, für den jeweiligen individuellen Patienten das für ihn am besten geeignete Verfahren auszuwählen.

    • 1 February 2014
      • Vol. 55  (1) , 9-19

    Current results of total endovascular repair of thoracoabdominal aortic aneurysms.

    by F Verzini, D Loschi, P De Rango, Ciro Ferrer, G Simonte, C Coscarella, G Pogany, P Cao

    Minimally invasive surgical solutions for patients with extensive aortic disease are eagerly awaited, since open repair is often associated with high rates of morbidity and mortality. In the last decade, the development of fenestrated and branched aortic endografts has offered a therapeutic option to patients deemed unsuitable for major surgery. Preliminary studies showed promising early results, while mid- and long- term data are scarce. The aim of this paper was to review current results of total endovascular repair of thoracoabdominal aortic aneurysms (TAAA) with a single model of endograft in the published literature. A literature search was conducted, and our two-center experience with fenestrated and branched endografts in the treatment of TAAA, with the Cook Zenith endograft, is presented. Early results show perioperative mortality rates ranging from 0% to 21%, spinal cord ischemia from 0% to 33.3%. At a mean follow up ranging from 9 to 19 months, reinterventions are needed in 3.3% to 25% of the cases, with a mid term visceral branch patency of 90% to 100%. Current experiences with total endovascular TAAA repair show promising results, in selected centers with large experience in complex aortic endografting. With increasing follow- up times, need for reintervention is growing, while aneurysm-related deaths remain rare. Long-term results are still lacking, but these encouraging data and further technological developments will support wider adoption of the technique.


  • Effect of Stentgraft Model on Aneurysm Shrinkage in 1,450 Endovascular Aortic Repairs

    by E. Cieri, P. De Rango, G. Isernia, G. Simonte, F. Verzini, G. Parlani, A. Ciucci, P. Cao

    • 1 February 2013
      • Vol. 54, 141-9

    Plaque debulking for femoro-popliteal occlusions: techniques and results.

    by M Lenti, A Marucchini, Giacomo Isernia, G Simonte, A Ciucci, P Cao, F Verzini

    Although currently there is a trend of using percutaneous transluminal angioplasty (PTA) and stenting for the treatment of long occlusions of superficial femoral artery, many studies reported comparable results in terms of mid- and long-term patency between PTA and stenting and plaque debulking techniques such as remote endarterectomy, directional atherectomy catheter atherectomy and laser guided atherectomy. A successful debulking procedure is strongly associated with patients comorbidities, length of lesions and clinical presentation. In the last decade many new devices have been proposed to improve debulking results. Despite encouraging data about technical feasibility and limb salvage rate, debulking is still associated with a low rate of long-term primary and secondary patency. However, randomized clinical trials are expected and can hopefully provide conclusions on the effective durability of these procedures.

    • 1 February 2012
      • Vol. 53, 179-88

    Results of the "endovascular treatment first" policy for infrapopliteal disease.

    by F Verzini, P De Rango, Giacomo Isernia, G Simonte, L Farchioni, P Cao

    Even though differences between first-bypass vs. first-endovascular approach in below the knee (BTK) lesions have never been adequately compared, endovascular strategy first approach can be currently successfully used to treat BTK lesions in patients with critical limb ischemia (CLI). Success however is strongly associated with risk groups, severity of disease and degree of clinical presentation beside the method of revascularization. From available data, the best results of endovascular first approach for BTK lesions can be achieved with multivessel and tibial (more than peroneal alone) recanalization and Rutherford 4 or 5 ischemia changes, especially if the correct angiosome can be revascularized (direct flow to the feeding artery of the foot) and there is no renal failure. For patients in Rutherford class 6 and extensive gangrene/tissue loss, BTK endovascular strategy alone does not seem to provide ideal results. Outcomes of interventional therapy for BTK lesions are consistently better when applied in experienced centers with the use of more advanced technology and use of eluting materials. According to limited but randomized evidence, drug-eluting stent (DES) placement might be recommended in BTK lesions under 40 mm long since yields significantly better results than angioplasty alone or implantation of bare metal stents in this lesion subset. Nevertheless, this policy raises doubts on the efficacy of treatment due to limitations in generalizability of outcomes in common hospital settings and related costs. Furthermore, there are still no consistent numbers to provide the efficacy of this approach and long-term data are lacking. Waiting for the long-term results of ongoing trials and new researches, a more comprehensive analysis of outcomes with BTK endovascular first strategy can be provided in the next future.


  • Trials in Progress

    by Piergiorgio Cao, Paola De Rango, Enrico Cieri, Fabio Verzini, Gianbattista Parlani

    Nine completed randomized clinical trials (RCTs) failed to show any advantage of carotid angioplasty and stenting (CAS) over carotid surgery, whereas a number of larger trials were recently developed and are still ongoing or have just released interim data analysis. These new RCTs, giving emphasis to CAS carried out with appropriate credentialing and updated technology should be appropriately powered. According to last published data, carotid revascularization performed by highly qualified surgeons and interventionalists might be safe and effective; nevertheless, stroke is more likely after carotid stenting, whereas myocardial infarction is more likely after surgery, and the 2 risks need to be balanced in selecting the indication for treatment in specific patients. It is hoped that ongoing RCTs will clarify a couple of other issues: (1) the benefit of CAS in “asymptomatic” patients with respect not only to surgery but also to medical therapy alone and (2) which subgroups of patients at “average risk” would benefit more from CAS. Final results from pending RCTs are eagerly awaited to manage the common practice with CAS.

    • 1 February 2010
      • Vol. 51  (1) , 53-69

    Endoleak after endovascular aortic repair: classification, diagnosis and management following endovascular thoracic and abdominal aortic repair.

    by P Cao, P De Rango, F Verzini, G Parlani

    Endoleak is a common and unique complication of endovascular aortic repair (EVAR) and its persistence represents a failure of the endovascular treatment. Accurate detection and classification is essential for the proper management since the method of endoleak treatment is determined by the different source. In general, high-pressure leaks (type I and type III) require urgent management because of the relatively high short-term risk of sac rupture. Although precise differentiation between type I and type III endoleaks may not be possible at cross- sectional imaging, differentiation is often unnecessary because both lesions are considered high-risk and require angiographic evaluation and subsequent treatment. Low-pressure lesions (types II and V or endotension) are considered less urgent but may warrant continued endovascular evaluation if there is impending growth of the aneurysm sac or if the patient presents with symptoms. Once detected, endoleaks warranting correction (all type I and III; persistent endotension and type II associated with aneurysm enlargement) are usually treated by endovascular route. A variety of techniques including extension endografts or cuff, balloon angioplasty, bare stents and a combination of transvascular and direct sac puncture embolization techniques has allowed to treat the vast majority of these endoleaks without conversion to open surgical repair. Type II endoleak continues to be the most common but also the most controversial in terms of evaluation, the need of treatment, and methods of treatment. Careful and rigorous postoperative lifelong follow-up with computed tomography (CT) and high quality imaging continue to be essential for all patients after EVAR.


    • 1 August 2009
      • Vol. 50  (4) , 483-92

    Different types of thoracic endografts.

    by P Cao, F Verzini, P De Rango, G Maritati, F De Pasquale, G Parlani

    The emerging role of stent-graft strategies for the management of thoracic aortic diseases has attracted growing acceptance, especially in considering the sobering results of open repair in thoracic high-risk settings (e.g., acute dissection, trauma, rupture). Aortic endograft technology for thoracic diseases has rapidly improved after the early use of first generation devices, and the new models show very promising early and mid-term success rates. To date there is no evidence of the superiority of any single device model over the others. Indeed, each device has some peculiarities that makes it more useful in specific settings. Current limitations in thoracic stent-grafts will hopefully be addressed with new designs of highly-individualized low-profile devices in order to extend the applicability of stent-graft technology in the thoracic aorta. Despite progress in configuration and flexibility and the greater availability of different devices compared to a decade ago, shortcomings of specific endovascular grafts including collapse, migration, or dislodgment have not been fully resolved. Nowadays the selection of patients on the basis of favourable anatomy and pathology is the key for the success of the procedure. Not all patients have lesions amenable to stent-graft repair (contraindications for endovascular treatment of thoracic aorta are still not marginal and mainly defined by anatomical constraints) and thoracic endografting is technically challenging, requiring dedicated facilities and experienced specialists. This paper discusses the different configurations and models of stent-graft for thoracic aortic disease as well as the still existing shortcomings.